PI
KLRS

Pennant Investors’s Kalaris Therapeutics KLRS Stock Holding History

Pennant Investors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,378
Closed -$156K – 46
2024
Q2 		$156K Hold
9,378
– – 0.04% 42
2024
Q1 		$163K Hold
9,378
– – 0.04% 42
2023
Q4 		$147K Buy
+9,378
New +$370K 0.03% 41

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Pennant Investors's KLRS Position: Q3 2024 in Review

Pennant Investors sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 9,378 shares — an estimated $156K sold.

Pennant Investors first reported a position in KLRS in Q4 2023 and held it in 3 quarters. The position peaked at $163K in Q1 2024. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Pennant Investors reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 9,378 Kalaris Therapeutics shares in Q3 2024, an estimated $156K.
  • Pennant Investors first reported a position in Kalaris Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Kalaris Therapeutics position peaked at $163K in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.